

X. REFERENCES AND NOTES

1. Di Marco, A. and Arcamone, F. (1975) DNA complexing antibiotics: daunomycin, Adriamycin and their derivatives. *Arzneimittel-Forschung* 25:368-375.
2. Meriwether, W. and Bachur, N. (1972) Inhibition of DNA and RNA metabolism by daunorubicin and Adriamycin in L1210 mouse leukemia. *Cancer Res.* 32:1137-1142.
3. Dorr, R. and Fritz, W. (1980) Doxorubicin *Cancer Chemotherapy Handbook*, pp. 388-401.
4. Fischl, M.A., Krown, S.E., O'Boyle, K.P., et al. (1993) Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. *J. AIDS* 6:259-264.
5. Gill, P.S., Rarick, M., McCutchan, J.A., et al. (1991) Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. *Am. J. Med.* 90:427-433.
6. Gerlowski, L.E. and Jain, R.K. (1986) Microvascular permeability of normal and neoplastic tissues. *Microvasc. Res.* 31:288-305.
7. Francis, N.D., Parkin, J.M., Weber, J., Boylston, A.W. (1986) Kaposi's sarcoma in acquired immune deficiency syndrome (AIDS). *J. Clin. Pathol.* 39:469-474.
8. Jain, R.K. (1987) Transport of molecules across tumor vasculature. *Cancer Metastasis Reviews* 6:559-593.
9. Seymour, L.W. (1992) Passive tumor targeting of soluble macromolecules and drug conjugates. *Crit. Rev. Ther. Drug Carrier Systems* 9:135-187.
10. Bielack, S.S., Erttmann, R., Winkler, K. and Landbeck, G. (1989) Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. *Eur. J. Cancer Clin. Oncol.* 25:873-882.
11. Legha, S.S., Benjamin, R.S., MacKay, B., Ewer, M., Wallace, S., Valdivieso, M., Rasmussen, S.L., Blumenschein, G.R. and Freireich, E.J. (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. *Ann. Int. Med.* 96:133-139.

12. Hortobagyi, G.N., Frye, D., Buzdar, A.U., Ewer, M.S., Fraschini, G., Hug, V., Ames, F., Montague, E., Carrasco, C.H., MacKay, B. and Benjamin, R.S. (1989) Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast cancer. *Cancer* 63:37-45.
13. Shapira, J., Gotfried, M., Lishner, M. and Ravid, M. (1990) Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen: a prospective randomized evaluation. *Cancer* 65:870-873.
14. Lokich, J., Bothe, A., Zipoli, T., Green, R., Sonneborn, H., Paul, S. and Philips, D. (1983) Constant infusion schedule for Adriamycin: a phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system. *J. Clin. Oncol.* 1:24-28.
15. Garnick, M.B., Weiss, G.R., Steele, G.D., Israel, M., Schade, D., Sack, M.J. and Frei, E. (1983) Clinical evaluation of long-term, continuous-infusion doxorubicin. *Cancer Treat. Rep.* 67:133-142.
16. Gabizon, A., Amselem, S., Goren, D., et al. (1990) Preclinical and clinical experience with a doxorubicin-liposome preparation. *J. Liposome Res.* 1:491-502.
17. Olson, F., Mayhew, E., Maslow, D., Rustum, Y. and Szoka, F. (1982) Characterization, toxicity and therapeutic efficacy of Adriamycin encapsulated in liposomes. *Eur. J. Cancer Clin. Oncol.* 18:167.
18. Sells, R.A., Gilmore, I.T., Owen, R.R., et al. (1987) Reduction in doxorubicin toxicity following liposomal delivery. *Cancer Treat. Rev.* 14:383-387.
19. Sells, R.A., Owen, R.R., New, R.R.C., et al. (1987) Reduction in toxicity of doxorubicin by liposomal entrapment. *The Lancet* 11:624-625.
20. Gabizon, A., Peretz, T., Sulkes, A., et al. (1992) Systemic administration of doxorubicin-containing liposomes in cancer patients: a Phase I study. *Eur. J. Cancer Clin. Oncol.* 25:1795-1803.
21. Owen, R.R., Sells, R.A., Gilmore, I.T., et al. (1992) A Phase I clinical evaluation of liposome-entrapped doxorubicin (Lip-dox) in patients with primary and metastatic hepatic malignancy. *Anti-cancer Drugs* 3:101-107.

22. Gabizon, A., Chisin, R., Amselem, S., Druckmann, S., Cohen, R., Goren, D., Fromer, I., Peretz, T., Sulkes, A., Barenholz, Y. (1991) Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated Adriamycin. *Br. J. Cancer.* 64:1125-1132.
23. Delgado, G., Potkul, R.K., Treat, J.A., et al. (1989) A Phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer. *Am. J. Obstet. Gynecol.* 160:812-819.
24. Rahman, A., Treat, J., Roh, J.K., Potkul, L.A., Alvord, W.G., Forst, D. and Woolley, P.V. (1990) A Phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. *J. Clin. Oncol.* 8:1093-1100.
25. Treat, J., Greenspan, A., Forst, D., Sanchez, J.A., Ferrans, V.J., Potkul, L.A., Woolley, P.V. and Rahman, A. (1990) Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: a Phase II study. *J. Natl. Cancer Inst.* 82:1706-1710.
26. Cowens, J.W., Kanter, P., Brenner, D.E., et al. (1989) Phase I study of doxorubicin encapsulated in liposomes (Abstract). *Proc. Am. Soc. Clin. Oncol.* 8:69.
27. Cowens, J.W., Creaven, P.J., Brenner, D.E., et al. (1990) Phase I study of doxorubicin encapsulated in liposomes (Abstract). *Proc. Am. Soc. Clin. Oncol.* 9:7.
28. Cowens, J.W., Greco, W., Ginsberg, R. (1990) Pharmacokinetics of doxorubicin encapsulated in liposomes in patients with advanced cancer (Abstract). *Proc. Am. Soc. Clin. Oncol.* 8:87.
29. Cowens, J.W., Creaven, P.J., Greco, D.E., et al. (1993) Initial clinical (phase I) trial of TLC-D99 (doxorubicin encapsulated liposomes). *Cancer Res.* 53:2796-2802.
30. Creaven, P.J., Cowens, J.W., Ginsberg, R., Ostro, M. and Browman, G. (1990) Clinical studies with liposomal doxorubicin. *J. Liposome Res.* 1:481-490.
31. Batist, G., Ahlgren, P., Panasci, J., et al. (1992) Phase II study of liposomal doxorubicin (TLC-D99) in metastatic breast cancer (Abstract). *Proc. Am. Soc. Clin. Oncol.* 11:82.

CONFIDENTIAL

DOXIL®
Liposome Technology, Inc.

Overall NDA Summary
August 29, 1994

32. Mazanet, R., Seidenberg, S., Bartel, S., Elias, A., Saletan, S. and Faber, D. (1993) A phase I study of liposome encapsulated doxorubicin (TLC-99) with G-CSF. (Abstract). *Proc. Amer. Soc. Clin. Oncol.* 12:154.
33. Conley, B., Egorin, M., Whitacre, M., Carter, D., Zuhowski, E. and Echo, D. (1993) Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. *Cancer Chem. Pharm.* 33:107-112.
34. Embree, L., Gelmon, K., Lohr, A., Mayer, L., Coldman, A., Cullis, P., Palaitis, W., Piliewicz, F., Hudon, N., Heggie, J. and Goldie, J. (1993) Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small lung cancer patients. *J. Pharm. Sci.* 82:627-634.
35. Kumai, K., Takahashi, T., Tsubouchi, T., et al. (1985) Selective hepatic arterial infusion of liposomes containing antitumor agents. *Jpn. J. Cancer Chemother.* 12:1946-1948.
36. Akamo, Y., Mizuno, I., Ichino, T., Yamamoto, T. et al. (1991) Endoscopic injection of liposomal Adriamycin targeting lymph node metastasis of gastric cancer. *Jpn. J. Cancer Chemother.* 18:1822-1824.
37. Juliano, R. and Stamp, D. (1975) The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. *Biochem. Biophys. Res. Comm.* 63:651.
38. Gregoriadis, G. and Senior, J. (1980) The phospholipid component of small unilamellar liposomes controls the rate of clearance of entrapped solutes from the circulation. *FEBS Lett.* 119:43.
39. Presant, C., Proffitt, R., Turner, A., Williams, L., Winsor, D., Werner, J., Kennedy, P., Wiseman, C., Gala, K., McKenna, R., Smith, J., Bouzaglou, S., Callahan, R., Baldeschweiler, J. and Crossley, R. (1988) Successful imaging of human cancer with indium-111-labeled phospholipid vesicles. *Cancer.* 62:905.
40. Presant, C.A., Scolaro, M., Kennedy, P., et al. (1993) Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. *Lancet* 341:1242.
41. Allen, T.M., Hansen, C., Martin, F., Redemann, C., Yau-Young, A. (1991) Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. *Biochim. Biophys. Acta.* 1066:29-36.

42. Gabizon, A., Barenholz, Y., Bialer, M. (1993) Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethyleneglycol-derivatized phospholipid: Pharmacokinetic studies in rodents and dogs. *Pharm. Res.* 10:703-708.
43. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A. and Barenholz, Y. (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes (DOXIL®). *Cancer Res.* 54:987-992.
44. Northfelt, D.M., Martin, F.J., Kaplan, L.D., et al. (1993) Pharmacokinetics, safety and tumor localization of DOXIL (liposomal doxorubicin) in AIDS patients with Kaposi's sarcoma. *Proc. ASCO* 12:51.
45. Huang, S.K., Lee, K.D., Hong, K., Friend, D.S. and Papahadjopoulos, D. (1992) Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. *Cancer Res.* 52:5135-5143.
46. Huang, S.K., Martin, F.J., Jay, G., et al. (1993) Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. *Am. J. Pathol.* 143:10-14.
47. Papahadjopoulos, D., Allen, T.M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S.K., Lee, K.D., Woodle, M.C., Lasic, D.D., Redemann, C., and Martin, F.J. (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and anti-tumor therapeutic efficacy. *Proc. Natl. Acad. Sci. (USA)* 88:11460-11464.
48. Huang, S.K., Mayhew, E., Gilani, S., Lasic, D.D., Martin, F.J. and Papahadjopoulos, D. (1992) Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. *Cancer Res.* 52:6774-6781.
49. Vaage, J., Barbera-Guillem, E., Abra, R., Huang, A. and Working, P. (1994) Tissue distribution and therapeutic effect of Intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. *Cancer.* 73:1478-1484.
50. Vaage, J., Donovan, D., Mayhew, E., Abra, R., and Huang, A. (1993) Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. *Cancer.* 72:3671-3675.

CONFIDENTIAL

DOXIL®
Liposome Technology, Inc.

Overall NDA Summary
August 29, 1994

51. Williams, S., Alosco, T., Mayhew, E., Lasic, D., Martin, F. and Bankert, R. (1993) Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. *Cancer Res.* 53:3964-3967.
52. Hengge, U.R., Brockmeyer, N., Baumann, M., Reimann, G., Goos, M. (1993) Liposomal doxorubicin in AIDS-related Kaposi's sarcoma. *Lancet.* 342:497.
53. Goebel, F.D., Bogner, J.R., Spathling, S., Held, M., Sandor, P., Trubenbach, K., Rauch, C.H. and Kronawitter, U. (1993) Quantitative ultrasound volume measurement serves as non-invasive method to follow response of cutaneous Kaposi's sarcoma lesions to Doxil therapy. (Abstract). *Proc. Amer. Soc. Clin. Oncol.* 12:51.
54. Bogner, J.R., Zietz, C., Held, M., Spathling, S., et al. (1993) Ultrasound as a tool to evaluate remission of cutaneous Kaposi's sarcoma. *AIDS* 7:1081-1085.
55. Simpson, J.K., Miller, R.F. and Spittle, M.F. (1993) Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcoma. *Clin. Oncol.* 5:372-374.
56. Report No. LTI-30-92-17. Multiple Dose Intravenous Toxicity Study of DOXIL (Stealth Liposomal Doxorubicin Hydrochloride) Injection in Rats.
57. Report No. LTI-30-94-07. Intravenous Multiple Dose Toxicity Study of DOXIL (Stealth Liposomal Doxorubicin Hydrochloride) in Beagle Dogs.
58. Pigram, W.J., Fuller, W. and Hamilton, L.D. (1972) Stereochemistry of intercalation. Interaction of daunomycin with DNA. *Nature* 235:17-19.
59. Pindur, U., Haber, M. and Sattler, K. (1993) Antitumor active drugs as intercalators of deoxyribonucleic acid. *J. Chem. Educ.* 4:263-272.
60. Zhang, H., Gao, Y., van de Marel, G.A., van Boom, J.H. and Wang, A.H.J. (1993) Simultaneous incorporations of 2 anticancer drugs into DNA. *J. Biol. Chem.* 268:10095-10101.
61. Hickman, J., Chahwala, S.B. and Thompson, E.G. (1985) Interaction of the antibiotic Adriamycin with the plasma membrane. *Adv. Enzym. Reg.* 24:263-274.

62. Santone, K.S., Oakes, S.G., Taylor, S.R. and Powis, G. (1986) Anthracycline-induced inhibition of a calcium action potential in differentiated neuroblastoma cells. *Cancer Res.* 46:2659-2664.
63. Erratum. No Reference Cited.
64. Pommier, Y., Schwartz, R.E., Zwelling, L.D. and Kohn, K.W. (1985) Effects of DNA intercalating agents on topoisomerase II-induced DNA strand cleavage in isolated mammalian cell nuclei. *Biochem.* 24:6406-6410.
65. Tewey, K.M., Rowe, T.C., Yany, L., Halligan B.D. and Liu, L.F. (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. *Science* 226:466-468.
66. Bachur, N.R., Gee, M.V. and Gordon, S.L. (1978) Enzymatic activation of actinomycin D ACTD to free radical state. *Proc. Amer. Assoc. Cancer Res.* 19:75.
67. Berlin, V. and Haseltine, W.A. (1981) Reduction of adriamycin to a semiquinone-free radical by NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen. *J. Biol. Chem.* 256:4747-4756.
68. Powis, G.P. (1987) Metabolism and reactions of quinoid anticancer agents. *Pharmacol. Therap.* 35:57-162.
69. Zwelling, L.A., Kerrigan, D. and Michael, S. (1982) Cytotoxicity and DNA strand breaks by 5-iminodaunorubicin in mouse leukemia L1210 cells: comparison with Adriamycin and 4'-(9-acridinylamino) methane sulfono-*m*-anisidine. *Cancer Res.* 42:2687-2691.
70. Speth, P.A.J., van Hoesel, Q.G.C.M. and Haanen, C. (1988) Clinical pharmacokinetics of doxorubicin. *Clin. Pharmacokin.* 15:15-31.
71. Greene, R.F., Collins, J.M., Jenkins, J.F., et al. (1982) Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. *Cancer Res.* 43:3417-3421.
72. Speth, P.A.J., Linssen, P.C.M., Holdrinet, R.S.G. and Haanen, C. (1987) Plasma and cellular adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion. *Clin. Pharmacol. Therap.* 41:661-665.

CONFIDENTIAL

DOXIL®
Liposome Technology, Inc.

Overall NDA Summary
August 29, 1994

73. Speth, P.A.J., Linssen, P.C.M., Boezeman, J.B.M., et al. (1987) Cellular and plasma Adriamycin concentrations in long-term infusion therapy of leukemia patients. *Cancer Chemother. Pharmacol.* 20:305-310.
74. Benjamin, R.S., Wiernik, P.H. and Bachur, N.R. (1974) Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. *Cancer* 33:19-27.
75. Yesair, D.W., Schwartzbach, E., Shuck, D., Denine, E.P. and Asbell, A.S. (1972) Comparative pharmacokinetics of Daunomycin and Adriamycin in several animal species. *Cancer Res.* 32:1177-1183.
76. Ozols, R.F., Locker, G.Y., Doroshow, J.H., Grotzinger, K.R., Myers, C.E. and Young, R.C. (1979) Pharmacokinetics of Adriamycin and tissue penetration in murine ovarian cancer. *Cancer Res.* 39:3209-3214.
77. Oosterbaan, M.J., Dirks, R.J., Vree, T.B., van der Kleijn, E. (1984) Pharmacokinetics of anthracyclines in dogs: evidence for structure-related body distribution and reduction to their hydroxy metabolites. *Pharm. Res.* 1:33-38.
78. Cusack, B.J., Young, S.P., Loseke, V.L., Hurty, M.R., Beals, L. and Olson, R.D. (1992) Effect of low-protein diet on doxorubicin pharmacokinetics in the rabbit. *Cancer Chemother. Pharmacol.* 30:145-148.
79. Druckmann, S., Gabizon, A. and Barenholz, Y. (1989) Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma. *Biochim. Biophys. Acta.* 980:381-384.
80. Riggs, C.E., Benjamin, R.S., Serpick, A.A. and Bachur, N.R. (1977) Biliary disposition of Adriamycin. *Clin. Pharmacol. Ther.* 22:234-241.
81. Benjamin, R.S., Riggs, C.E. and Bachur, N.R. (1977) Plasma pharmacokinetics of Adriamycin and its metabolites in humans with normal hepatic and renal function. *Cancer Res.* 37:1416-1420.
82. Takanashi, S. and Bachur, N.R. (1976) Adriamycin metabolism in man, evidence for urinary metabolites. *Drug Metab. Dispos.* 4:79-87.
83. Bachur, N.R. (1975) Adriamycin (NSC-123127) pharmacology. *Cancer Chemother. Rep.* 6:153-158.

84. Dessypris, E.N., Brenner, D.E., Krantz, S.B. and Hande, K.R. (1984) Toxicity of adriamycin metabolites in human bone marrow erythroid and myeloid progenitors in vitro. *Cancer Res.* 25:1203a.
85. Bachur, N.R., Steele, M., Meriwether, N.D., et al. (1976) Cellular pharmacodynamics of several anthracycline antibiotics. *J. Med. Chem.* 19:651-654.
86. Harris, P.A. and Gross, J.F. (1975) Preliminary pharmacokinetic model for Adriamycin. *Cancer Chemother. Rep.* 59:819-825.
87. Lee, Y.N., Chan, K.K., Harris, I.H. and Cohen, J.L. (1980) Distribution of Adriamycin in cancer patients, tissue uptakes, plasma concentrations after intravenous and hepatic intraarterial administration. *Cancer* 45:2231-2239.
88. Di Fronzo, A., Lenaz, L. and Bonadonna, G. (1973) Distribution and excretion of Adriamycin in man. *Biomed.* 19:169-171.
89. Riggs, C.E. and Bachur, N. (1983) Clinical pharmacokinetics of anthracycline antibiotics, In: Pharmacokinetics of Anticancer Agents in Humans, (M.M. Ames, G. Powis and J.S. Kovach, eds.), Elsevier, Amsterdam, pp. 229-258.
90. Senior, J.H. (1987) Fate and behavior of liposomes in vivo: a review of controlling factors. *CRC Crit. Rev. Ther. Drug Carrier Sys.* 3:121-193.
91. Abra, R.M. and Hunt, C.A. (1981) Liposome disposition in vivo. III. Dose and vesicle-size effects. *Biochim. Biophys. Acta* 666:493-503.
92. Woodle, M.C., Newman, M.S., Collins, L., Redemann, C. and Martin, F.J. (1990) Improved long circulating (Stealth) liposomes using synthetic lipids. In: Proc. 17th Int. Symp. Controlled Rel. Bioact. Mater. 17:77-78.
93. Davis, H. and Davis, T.E. (1979) Daunorubicin and Adriamycin in cancer treatment: An analysis of their role and limitation. *Cancer Treat. Rep.* 63:809-815.
94. Muggia, F.M., Young, C.W. and Carter S.K. (Eds.) (1982) Anthracycline Antibiotics in Cancer Therapy, The Hague: Martinus Nijhoff Publishers.
95. Maral, R.J. and Jouanne, M. (1981) Toxicology of daunorubicin in animals and man. *Cancer Treat. Rep.* 65 (Suppl. 4):9-18.

96. Wright, J.C. (1984) Cancer chemotherapy: past, present and future - Part I. J. Nat. Med. Assoc. 76:773-784.
97. Legha, S.S., Hortobagyi, G.N. and Benjamin, R.S. (1987) Anthracyclines. In: Cancer Chemotherapy by Infusion, (J.J. Lokich, Ed.), Precept Press, Chicago, pp. 130-144.
98. Thompson, D., Molello, J.A., Strebing, R.J. and Dyke, I.L. (1978) Teratogenicity of Adriamycin and Daunomycin in the rat and rabbit. Teratology 17:151-158.
99. Lokich, J.J. and Moore, C. (1984) Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Annals Int. Med. 101:798-800.
100. Vogelzang, N.J. and Ratain, M.J. (1985) Cancer chemotherapy and skin changes. Annals Int. Med. 103:303-304.
101. Samuels, B.L., Vogelzang, N.J., Ruane, M. and Simon, M.A. (1987) Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treat. Rep. 71:971-972.
102. Aukland, S.P., Ratain, M.J., Vogelzang, N.J., Choi, K.E., Ruane, M. and Sinkule, J.A. (1989) Pharmacokinetics and pharmacodynamics of long-term continuous infusion of doxorubicin. Clin. Pharmacol. Ther. 45:340-347.
103. Dantchev, D., Slioussartchouk, V., Paintrand, M., Hayat, M., Bourut, C. and Mathe, G. (1979) Electron microscopic studies of the heart and light microscopic studies of the skin after treatment of Golden hamsters with Adriamycin, Detorubicin, AD-32 and Aclacinomycin. Cancer Treat. Rep. 63:875-888.
104. Physicians' Desk Reference (1991) 45th Edition, Medical Economics Data, Oradell, NJ, pp. 559-562.
105. Lu, C.C. and Meistrich, M.L. (1979) Cytotoxic effects of chemotherapeutic drugs on mouse testis cells. Cancer Res. 39:3575-3582.
106. Chapman, R.M., Sutcliffe, S.B., Rees, L.H., Edwards, C.R.W. and Malpas, J.S. (1979) Cyclical combination chemotherapy and gonadal function. Lancet 1:285-289.

CONFIDENTIAL

DOXIL®
Liposome Technology, Inc.

Overall NDA Summary
August 29, 1994

107. Whitehead, E., Shalet, S.M., Blackledge, G., Todd, I., Crowther, D. and Beardwell, C.G. (1982) The effects of Hodgkin's disease and combination chemotherapy on gonadal infusion in the adult male. *Cancer* 49:418-422.
108. Fuse, H., Iwasaki, M. and Katayama, T. (1992) Endocrine/histological parameters of spermatogenic damage in doxorubicin-treated rats. *Adv. Cont. Deliv. Syst.* 8:33-40.
109. Rudolph, R., Stein, R.S. and Pattillo, R.A. (1976) Skin ulcers due to Adriamycin. *Cancer* 38:1087-1094.
110. Rudolph, R. and Larson, D.L. (1987) Etiology and treatment of chemotherapeutic agent extravasation injuries: a review. *J. Clin. Oncol.* 5:1116-1126.
111. Minow, R.A., Benjamin, R.S., Lee, E.T. and Gottlieb, J.A. (1977) Adriamycin cardiomyopathy: risk factors. *Cancer* 39:1397-1402.
112. Von Hoff, D.D., Layard, M.W., Basa, P., et al. (1979) Risk factors for doxorubicin-induced congestive heart failure. *Ann. Intern. Med.* 91:710-717.
113. Chlebowski, R.T., Paroly, W.S., Pugh, R.P., et al. (1980) Adriamycin given as a weekly schedule with a loading course: Clinically effective with reduced incidence cardiotoxicity. *Cancer Treat. Rep.* 64:47-51.
114. Legha, S.S., Benjamin, R.S., Mackay, B., et al. (1982) Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. *Cancer* 49:1762-1766.
115. Garnick, M.B., Weiss, G.R., Steele, G.D. et al. (1983) Clinical evaluation of long-term continuous infusion doxorubicin. *Cancer Treat. Rep.* 67:133-142.
116. Riggs, C.E., Benjamin, R.S., Serpick A.A. and Bachur, N.R. (1977) Biliary disposition of Adriamycin. *Clin. Pharmacol. Ther.* 22:234-241.
117. Report on the Task Group on Reference Man. International Commission on Radiological Protection, No. 23. (Snyder WS, Cook, MJ, Nasset ES, Karhausen R, Howells GP and Tipton IH, eds.). Pergamon Press, New York, pp.

CONFIDENTIAL

DOXIL®
Liposome Technology, Inc.

Overall NDA Summary
August 29, 1994

118. Timour, Q., Nony, P., Lang, J., et al. (1987) Doxorubicin concentration time course in the myocardium after single administration to the dog. *Cancer Chemother. Pharm.* 20:267-269.
119. Cummings, J. and McArdle, C.S. (1986) Studies on the in vivo disposition of Adriamycin in human tumors which exhibit different responses to the drug. *Br. J. Cancer* 3:835-838.
120. Vogel, J., Hinrichs, S.H., Reynolds, R.K., Luciw, P.A. and Jay, G. (1988) The HIV *tat* gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. *Nature* 335:606-611.
121. Report LTI-30-05. Randomized, pharmacokinetic, dose-finding and tumor localization study of Stealth® liposomal doxorubicin hydrochloride compared to Adriamycin® in patients with AIDS and Kaposi's sarcoma.
122. Krown, S.E., Metroka, C. and Wernz, J.C. (1989) Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response and staging criteria. *J. Clin. Oncol.* 7:1201-1207.
123. Vogelzang, N.J. and Ratain, M.J. (1985) Cancer chemotherapy and skin changes. *Annals Int. Med.* 103:303-304.
124. Autran, B.R., Gorin, I., Lerbowitch, M. (1983) AIDS in a Haitian Woman with Cardiac Kaposi's Sarcoma and Whipple's Disease. *Lancet* 1:767-8.
125. Kaul, S., Fishbein, M.C., and Siegel, R.J. (1991) Cardiac Manifestations of Acquired Immunodeficiency Syndrome: A 1991 Update. *Amer. Heart J.* 122:535-544.
126. Herskowitz, A., Vlahov, D., Willoughby, S., et al. (1993) Prevalence and Incidence of Left Ventricular Dysfunction in Patients with Human Immunodeficiency Virus Infection. *Amer. J. Cardiol.* 71:955-958.
127. Lewis, W. (1989) AIDS: Cardiac Findings from 115 Autopsies. *Prog. Cardiovasc. Dis.* 32:207-215.
128. Aretz, H.T., Billingham, M.E., Edwards, W.D., et al. (1986) Myocarditis a Histopathologic Definition and Classification. *Am. J. Cardiovasc. Pathol.* 1:1-14.

129. Calabrese, L.H., Proffitt, M.R., Yen-Liebermann, B. (1987) Congestive Cardiomyopathy and Illness Related to the Acquired Immunodeficiency Syndrome (AIDS) Associated with Isolation of Retrovirus from Myocardium. *Ann. Int. Med.* 107:691-692.
130. Grody, W.W., Cheng, L., Lewis, W. (1990) Infection of the Heart by the Human Immunodeficiency Virus. *Am. J. Cardiol.* 66:203-206.
131. Lewis, W., Papoian, T., Gonzales, B., Louie, H., Kelly, D., Payne, R.M., Grody, W. (1991) Mitochondrial Ultrastructural and Molecular Changes Induced by Zidovudine in Rat Hearts. *Lab. Invest.* 65:228-236.
132. Dalakas, M., Illa, I., Pezeshkpour, G.H., Laukaitis, J., Cohen, B., Griffin, J. (1990) Mitochondrial Myopathy Caused By Long-Term Zidovudine Therapy. *N. Engl. J. Med.* 322:1098-1105.
133. Herskowitz, A., Willoughby, S., Baughman, K., Schulman, S., Bartlett, J. (1992) Cardiomyopathy Associated with Antiretroviral Therapy in Patients with HIV Infection: A Report of Six Cases. *Ann. Int. Med.* 116:311-313.
134. Anderson, D.W., Virmani, R. (1990) Emerging Patterns of Heart Disease in Human Immunodeficiency Virus Infection. *Hum. Pathol.* 21:253-259.
135. A search of MedLine and EmBase electronic databases was conducted on July 15, 1993 using the keywords set "doxorubicin/liposome/human." 128 unique citation were identified using this strategy. Upon review, 16 of these were found to contain safety and other information on patients administered liposomal doxorubicin. Seven abstracts relating to these publications were subsequently identified. Six additional publications were identified following a review of clinical articles appearing after this search was completed and before June 1, 1994. It was not possible to obtain a translation of the one Japanese language article by Mizuno et al, 1991.
136. Cohen, P.R. (1993) Acral Erythema: A Clinical Review. *Curtis* 51:175-179.
137. Kahn, J.O., Northfelt, D.W. and Miles, S.A. (1992). AIDS-associated Kaposi's sarcoma. *In: AIDS Clinical Review* (PA Volberding and MA Jacobson, eds.). Marcel Dekker, New York, pp. 261-280.

CONFIDENTIAL

DOXIL®
Liposome Technology, Inc.

Overall NDA Summary
August 29, 1994

138. Peters, B.S., Beck, E.J., Coleman, D.G., et al. (1991) Changing disease patterns in patients with AIDS in a referral centre in the United Kingdom: the changing face of AIDS. *Brit. Med. J.* 302:203-206.
139. Laubenstein, J.L., Krigel, R.L., Odajnyk, C.M., et al. (1984) Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin and vinblastine. *J. Clin. Oncol.* 2:115-120.
140. Munoz, A., Schrag, L.K., Bacellar, H., et al. (1993) Trends in the incidence of outcome defining Acquired Immunodeficiency Syndrome (AIDS) in the multicenter AIDS cohort study: 1985-1991. *Am. J. Epidemiol.* 137:423-438.
141. Gallant, J.E., Moore, R.D., Richman, D.D., et al. (1992) Incidence and natural history of cytomegalovirus disease in patients with advanced Human Immunodeficiency Virus disease treated with zidovudine. *J. Infect. Dis.* 166: 1223-1227.
142. Von Hoff, D.D., Rozencweig, M. and Piccart, M. (1982) The cardiotoxicity of anticancer agents. *Semin. Oncol.* 9:23-33.
143. Herskowitz, A., Willoughby, S, Wu, T-C., et al. (1993) Immunopathogenesis of HIV-1-associated cardiomyopathy. *Clin. Immunol. Immunopathol.* 68:234-241.
144. Evans, L.M., Itri, L.M., Campion, M., et al. (1991) Interferon- α_2a in the treatment of Acquired Immunodeficiency Syndrome-related Kaposi's sarcoma. *J. Immunother.* 10:39-50.